By proceeding, you agree to our Terms of Use and Privacy Policy.
Certis began its journey in precision medicine, helping individual cancer patients and their oncologists determine--with certainty--the best available treatments for their unique cancers.
12-14 July 2022
From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models – Deepen Our Understanding of Tumor Biology, Resistance Mechanisms & Dosing Strategy Following the success of KRAS, HER2, BCMA, drug developers ha
Event Ended
USA
Paid
Boston
07-08 December 2022
With next generation of complex immuno-oncology candidates, preclinical and translational scientists in the IO space are in need for more predictive tumour models to improve clinical translatability, accelerating speed-to-clinic with confidence.
UK
London
24-26 January 2023
With 2023 on track to see further growth in the immuno-oncology field, the availability of tools that offers drug developers & researchers advantages that weren’t available to them even a few years ago is increasing rapidly.
San Francisco
12-13 July 2023
The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encourage